Vaccine for prophylaxis or treatment of an allergen-driven airway pathology
US11110161B2 · kind B2 · utility
3Cited by
0References
6Claims
0Family size
Inventors
Key dates
| Filing date | Apr 3, 2020 |
| Grant date | Sep 7, 2021 |
| Priority date | — |
| Expiry date | Apr 3, 2040 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/544
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a live attenuated Bordetella pertussis vaccine which is deficient for tracheal cytotoxin (TCT), pertussis toxin (PTX), and dermonecrotic toxin (DNT) for prophylaxis or treatment of an allergen-driven airway pathology.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.